{"id":951,"date":"2026-07-29T11:52:00","date_gmt":"2026-07-29T02:52:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-07-29-personalized-lung-cancer-dna-vaccine-en\/"},"modified":"2026-07-29T13:52:57","modified_gmt":"2026-07-29T04:52:57","slug":"2026-07-29-personalized-lung-cancer-dna-vaccine-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-07-29-personalized-lung-cancer-dna-vaccine-en\/","title":{"rendered":"A vaccine built from one cancer\u2019s blueprint reaches its first UK patient"},"content":{"rendered":"<p><strong>2026-07-29 11:52 KST<\/strong><\/p>\n<p>NEOVACC, a DNA vaccine designed from the unique mutations in one patient\u2019s tumour, has been administered to its first UK patient.<\/p>\n<p>This is a first-in-human study in a narrowly selected group with existing lung cancer; it is testing safety and immune response and has not proved that the vaccine treats cancer.<\/p>\n<h2>Why every vaccine is different<\/h2>\n<p>Researchers compare DNA from a tumour biopsy with normal cells, then use computation to select tumour changes that the immune system may recognize. Those targets become one patient\u2019s vaccine design.<\/p>\n<p>Two people with the same diagnosis can have different mutation combinations, so this is not a standard preventive vaccine given identically to everyone.<\/p>\n<h2>What doggybone DNA means<\/h2>\n<p>The target instructions are placed in linear closed DNA made enzymatically without bacterial fermentation. Its closed ends give the doggybone DNA platform its name.<\/p>\n<p>A needle-free injector delivers it into muscle. The registration schedules dosing every three weeks for 24 weeks and then every six weeks alongside pembrolizumab.<\/p>\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/onepress.co.kr\/wp-content\/uploads\/2026\/07\/personalized-lung-cancer-dna-vaccine-en.png\" alt=\"Biomedical visualization connecting tumour biopsy analysis to personalized DNA and a needle-free injector\" loading=\"lazy\" \/><figcaption class=\"op-briefing-image-caption\">Produced explanatory image: it depicts the personalized DNA-vaccine workflow and is not a photograph of a NEOVACC patient, product or laboratory.<\/figcaption><\/figure>\n<h2>Who the trial is for<\/h2>\n<p>Eligible adults have advanced or recurrent non-small-cell lung cancer, PD-L1 expression of at least 50%, and disease not cleared by standard anti-PD-1 treatment.<\/p>\n<p>People with rapidly progressing disease who cannot wait for manufacturing, or those already in complete response, are among those excluded. It is not generally available care.<\/p>\n<h2>What the first dose proves and does not prove<\/h2>\n<p>The administration shows that biopsy, target selection, individualized production and delivery can reach a patient. Blood and repeat biopsies will test immune recognition and monitor adverse effects.<\/p>\n<p>There are no results yet for tumour shrinkage, relapse prevention or survival. A personalized design is not itself evidence of clinical efficacy.<\/p>\n<h2>What to watch next<\/h2>\n<p>The study will examine whether vaccine-induced T cells recognize the selected cancer targets. The official registry lists the trial as ongoing and no results publication is available.<\/p>\n<p>Safety, manufacturing time, actual enrollment and immune-response data will determine whether a larger efficacy trial is justified.<\/p>\n<h2>Official primary sources<\/h2>\n<p><a href=\"https:\/\/www.ukri.org\/news\/first-uk-patient-given-bespoke-lung-cancer-therapy-vaccine\/\" target=\"_blank\" rel=\"noopener noreferrer\">Primary source: UK Research and Innovation first-patient announcement<\/a><\/p>\n<p><a href=\"https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/neovacc\/\" target=\"_blank\" rel=\"noopener noreferrer\">Primary source: UK Health Research Authority NEOVACC summary<\/a><\/p>\n<p><a href=\"https:\/\/www.isrctn.com\/ISRCTN11752949\" target=\"_blank\" rel=\"noopener noreferrer\">Primary source: ISRCTN11752949 official trial registration<\/a><\/p>\n<p><a href=\"https:\/\/www.clatterbridgecc.nhs.uk\/about-us\/news\/new-cancer-vaccine-clinical-research-trial-open-clatterbridge-patients\" target=\"_blank\" rel=\"noopener noreferrer\">Primary source: Clatterbridge Cancer Centre trial announcement<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEOVACC reads a patient\u2019s tumour mutations to make an individual DNA vaccine. The first UK patient has received it, but this first-in-human trial is testing safety and immune response, not proven benefit.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-951","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}